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Abstract
Recent reports highlight the severity and the morbidity of disease caused by the long neglected malaria parasite
Plasmodium vivax. Due to inherent difficulties in the laboratory-propagation of P. vivax, the biology of this parasite has not
been adequately explored. While the proteome of P. falciparum, the causative agent of cerebral malaria, has been
extensively explored from several sources, there is limited information on the proteome of P. vivax. We have, for the first
time, examined the proteome of P. vivax isolated directly from patients without adaptation to laboratory conditions. We
have identified 153 proteins from clinical P. vivax, majority of which do not show homology to any previously known gene
products. We also report 29 new proteins that were found to be expressed in P. vivax for the first time. In addition, several
proteins previously implicated as anti-malarial targets, were also found in our analysis. Most importantly, we found several
unique proteins expressed by P. vivax.This study is an important step in providing insight into physiology of the parasite
under clinical settings.
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Introduction
Plasmodium vivax has been long neglected as a major malaria
parasite since it is the causative agent of benign malaria, in favor of
Plasmodium falciparum that causes fatal cerebral malaria. However,
P. vivax is the second leading cause of malaria outside Africa
inflicting about 40% of the world population. In Asia, P. vivax
accounts for about 50% of malaria cases [1]. P. vivax is known to
cause severe morbidity in individuals infected with this parasite
leading to paroxysmic fever, severe anemia and thrombocytopenia
[1]. Although drug-resistant species of both P. vivax as well as P.
falciparum have been reported, P. vivax vaccine and drug target
discovery operate only in the wake of P. falciparum vaccine and
drug target development [2].
Evidences from recent studies have suggested significant
differences in the gene families employed by these parasites.
Genome analysis of P. vivax isolated from malaria patients have
shown that in spite of its resemblance with other malaria parasites
in its gene content and metabolic processes, P. vivax possesses novel
gene families and alternative invasion pathways [3]. These
differences may lead to distinctive clinical features of P. vivax.
For example, unlike P. falciparum which infects red blood cells, P.
vivax preferentially infects reticulocytes expressing Duffy blood
group antigens (Fya and Fyb), which act as receptors for proteins
PvRBP1 and PvRBP2 expressed at the apical pole of P. vivax
merozoites. Additionally, the presence of hypnozoite stage and the
absence of cytoadherence in P.vivax make its biology different from
that of P. falciparum. Due to these differences in the biology as well
as clinical properties of P. vivax and P. falciparum, our knowledge of
P. falciparum cannot be extrapolated to P. vivax.
One of the major hurdles in the study of P. vivax-malaria is the
absence of a long-term in vitro culture system, unlike P. falciparum
[4]. As a result, our knowledge about P. vivax is limited to a few
studies that have been carried out using short-term cultures of P.
vivax and clinically isolated parasites. Our current understanding
about the P. vivax life cycle is restricted only to the information
provided by the global transcriptome analyses of this parasite from
clinical samples and limited proteomics analysis of only schizont
stage P. vivax parasites that have been culture adapted [5,6,7].
Although transcriptome analysis provides useful understanding at
the level of gene expression, they do not reflect the active protein
component of a cell. Further, parasites such as Plasmodium, interact
with and respond to host environmental cues which can often be
revealed by proteomic analyses of the parasite as it is present
within the host. However unlike P. falciparum, the proteome of this
parasite has not yet been explored either from short-term culture
adapted parasites or parasites directly isolated from malaria
patients. Dearth of any available information regarding the active
protein profile employed by this parasite in order to invade and
establish infection in humans makes it imperative to carry out
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proteomic analysis of the parasite directly isolated from patients
who suffer from vivax-malaria. This will indeed facilitate deeper
understanding of the pathology of this disease. The proteomic
analysis of P. vivax, however, is hampered by limited parasitemia of
usually ,0.5%, seen in case of P. vivax infections as it infects only
reticulocytes, which comprise 1–3% of the total RBCs [8]. This is
in contrast to P. falciparum which is able to infect RBCs of all ages,
resulting in a relatively higher average parasitemia of .5%.
Our previous study [9] gave the first ever insight into the
proteome of malarial parasites at the clinical level. In the case of P.
falciparum a reference proteome from lab cultures existed prior to
the analysis of the clinical proteome [10,11]. However, knowledge
of P. vivax proteome is extremely limited [7]. In this study, we
report the first ever in-depth proteomic analysis of P. vivax isolated
directly from malaria patients. We were able to identify 153
proteins from the blood stages of P. vivax. Interestingly, more than
36% of the parasite proteome comprised of hypothetical proteins.
We were also able to identify 16 proteins for which there are no
homologs in P. falciparum. Overall, our analysis reinforces the belief
that P. vivax biology needs to be examined independent of P.
falciparum and has several novel features unique to this organism
that can be exploited for therapeutic intervention against this
major parasite.
Materials and Methods
Ethics Statement
The present study has been approved by the Institutional
Scientific Advisory Committee of National Institute of Malaria
Research (ICMR), New Delhi, India. A written informed consent
was obtained from each patient participated in this study.
Collection of Parasites from Patients
5 ml of blood was collected in heparin coated tubes from
patients diagnosed with malaria (with written informed consent).
Microscopic examination of peripheral blood smear was done for
the presence of malarial parasites. Additionally, Falcivax rapid
diagnostic test based on PfHRP-2 and P. vivax specific LDH was
used for the differentiation of P. falciparum and P. vivax malaria.
Samples positive only for P. vivax were used for this study. Here we
must mention that RDT may sometimes detect mixed infections of
P. vivax with P. falciparum. In order to avoid this, more specific tests
such as nested PCR can be performed. However, since samples
used in our study were directly taken from patients for proteomics-
processing, we have ensured greater stringency during data
analyses as detailed below.
Sample Preparation
Parasitized whole blood cells were centrifuged at 1,500 g for
15 min for the removal of plasma and buffy coat. Blood pellet thus
obtained was diluted with PBS and was layered on Histopaque
(Sigma Aldrich) for the removal of white blood cells. P. vivax
infected cells was purified from uninfected cells by layering the cell
suspension on a 45, 50 and 65% Percoll gradient. An enriched
fraction of asexual stages of P. vivax was obtained with little
contamination of host cells. For extraction of P. vivax proteins,
enriched parasitized cells were either boiled directly in SDS
sample buffer or lysed with Saponin (Fluka) to obtained soluble
and insoluble fractions. Saponin insoluble pellets were further
processed as described earlier [12]. Briefly, the saponin pellet was
lysed first in Triton X containing buffer, Buffer A (10 mM Tris
HCl, pH 7.4; 5 mM EDTA; 1% Triton X 100) followed by lysis in
urea containing buffer, Buffer B (10 Mm Tris HCl, pH 7.4; 5 mM
EDTA; 1% SDS; 6 M Urea). Soluble fractions obtained at each
step were acetone precipitated and the final insoluble pellet was
directly boiled in SDS loading buffer. Purified parasites or saponin
pellet was maintained at 4uC throughout the lysis procedure. All
theses samples were separated on a 10% SDS-PAGE followed by
in gel digestion as described by Wilm et al. 1996 with slight
modification [13]. In brief, each lane was cut into pieces of width
2 mm. These pieces were further chopped into small pieces, which
were reduced with 10 mM dithiotreitol followed by alkylation
using 55 mM iodoacetamide. Alkylated gel pieces were incubated
with 400 ng of trypsin (20 ml of trypsin from the solution of 20 ng/
ml trypsin (Trypsin Gold, Promega), in 25 mM NH4OAc for 14–
16 hr at 37uC. Trypsin digested peptides were eluted from the gel
pieces using 60% acetonitrile (ACN) and 5% formic acid and were
subjected to LC-MS/MS.
Nano LC-MS/MS analysis of malaria proteins
Digested peptides were analyzed by nano LC- MS/MS as
described previously [8]. Briefly, peptide mixtures were dissolved
in 25 ml of sample preparation solution (98% water, 2%
Acetonitrile and 0.5% Formic acid) and injected into Nano-LC
through an autosampler system. Peptides were eluted using nano-
reverse phase column (Michrom C18 5 m 300 A˚) which was
further connected to the Nano Spray ESI- QTOF system (Qstar
Elite, Applied Biosystems). A gradient of water and acetonitrile
was set up for 60 minutes with a flow rate of 400 nL/minute.
Eluted peptides from the column were ionized using ESI source
with ion spray voltage 2250 V and temperature 120uC. Ionized
peptides were analyzed by one full MS scan and four consecutive
product ion scans of the four most intense peaks, using rolling
collision energy. An Information Dependant Acquisition (IDA)
experiment was used to specify the criteria for selecting each
parent ion for fragmentation which included selection of ions in
m/z range: .400 and ,1600, of charge state of +2 to +5,
exclusion of former target ions for 30 seconds, accumulation time
of 1 second for a full scan and 2 seconds for MS/MS. The data
generated by the Analyst software was stored in a .wiff format.
Data Analysis
Data was analyzed using ProteinPilot version 4.0 software. The
original data files were analyzed using the ProteinPilot version 4.0
software with a combined database (NCBI Human DB 2008
(containing 39125 non-redundant protein entries, 18.8 Mb),
PlasmoDB Plasmodium vivax version 7.1 (containing 5432 redun-
dant protein entries, 4.4 Mb), and PlasmoDB Plasmodium falciparum
October 2008 (containing 11669 redundant protein entries,
4.8 Mb) with a total of 56226 protein entries using Paragon
Algorithm. The number of missed cleavages permitted was two.
During the analysis, in the search parameters modification of
cysteine by idoacetamide and biological modifications pro-
grammed in algorithm were allowed. Mass tolerance for precursor
ion and fragment ions were set to 100 ppm and 0.2 Da
respectively. In Paragon Algorithm, protein score is calculated
on the basis of percentage confidence level of the peptides
identified. Protein score of minimum 0.47 (fit incorrect rate is 0%)
corresponding to a confidence level greater than 66% were used.
Several P. vivax proteins detected had a score of less than 0.47 and
these have been included in a separate list in Table S6.
In order to rule out false discoveries, we have carried out False
Discovery Rate (FDR) analysis. For this, ProteinPilot 4.0 with
Paragon algorithm has been used for data analysis. As part of the
Paragon analysis method, a false discovery rate (FDR) analysis of
the results has been carried out by the Proteomics Performance
Evaluation Pipeline Software (PSPEP). Finally, proteins have been
selected on the basis of their critical FDR value i.e. 1%.
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In order to avoid identifications based on redundant peptides in
our proteome, we have not included proteins that have no unique
peptide identifications (Table S4). Proteins which share some
peptides as well as have unique peptide-identifications, have been
grouped accordingly.
Annotation of hypothetical proteins
About 36% of the P. vivax proteome consisted of hypothetical
proteins. We have carried out sequence based domain search
using the SMART and Pfam tools and identifying domains present
in them. A molecular class was assigned to the hypothetical
proteins based on the identified domain.
Results
Functional classification of proteins expressed by P. vivax
To study the proteome of P. vivax, we collected peripheral blood
from P. vivax infected patients attended to the OPD of Wenlock
Government Hospital, Mangalore, Karnataka, India and S.P.
Medical College and Associated Group of Hospitals, Bikaner, India.
P. vivax infected blood was collected before administration of any
drugs. To minimize the host proteins contamination parasitized
erythrocytes were purified by percoll density gradient as described
in ‘‘Materials and Methods’’. A typical sample consisting of about
5 mL of parasitized blood of 0.1% parasitemia contains 16107
infected reticulocytes. However, at each step of purification there is a
loss of sample which therefore, resulted in a 16105 infected
reticulocytes after percoll purification. Proteins were extracted from
enriched fraction either by directly boiling in sample buffer or by
sequential lysis using SDS containing buffer or urea containing buffer.
After each lysis step proteins were separated on SDS-PAGE
(Figure 1B). Each of these lanes were divided into 10 pieces and
were subjected to in-gel trypsin digestion. Digested peptides were
extracted in 60% ACN and 5% formic acid and were analyzed by
LC-MS/MS-QTOF. The representative TIC, MS and MS/MS
spectra for one of the sample is given in Figure 1C. We were able to
identify 137 proteins from the asexual stages of P.vivax. In our
previous study, we have identified 16 P. vivax proteins. Altogether, we
here represent 153 proteins expressed by asexual stages of P. vivax
(Table S1). P. vivax proteome comprises of proteins consisting of
chaperones, glycolytic enzymes, signaling proteins, RNA processing,
chromatin and chromosome organization, cytoskeleton organization,
transport, virulence, transcription and translational regulatory and
hypothetical proteins (Figure 2A). Majority of these proteins belong to
Figure 1. Mass spectrometric analysis of proteins employed by asexual stages of P. vivax. A. Giemsa-stained image of peripheral blood
smear of P. vivax infected patient. B. SDS-PAGE profile of proteins extracted from asexual stages of P. vivax by sequential lysis using SDS buffer (lane
1), urea containing buffer (lane 2) and direct boiling of pellet in Laemmli buffer (lane 3). C. Represents the Total Ion Chromatogram (TIC), MS, and MS/
MS spectra for enolase (PVX_095015).
doi:10.1371/journal.pone.0026623.g001
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the hypothetical protein group followed by proteins involved in
metabolic processes, protein folding (chaperones and co-chaperones)
and pathogenicity. Based on the presence of domains, we have
classified hypothetical proteins into various categories along with
other annotated proteins as described below. Of all the hypothetical
proteins about 76% did not contain any identifiable domains. From
here onwards, the annotated hypothetical proteins are no longer
analyzed as hypothetical proteins. Instead, they are categorized as
proteins with known putative functions (Figure 2B) (Table S2).
Additionally, we have identified 7 proteins which were entirely
specific to P. vivax (do not contain homologs in any Plasmodium
species) and 16 proteins for which there were no homologs in P.
falciparum (Table 1). Of the 16 proteins that did not have homologs
in P. falciparum, 2 were Vir proteins and 8 were P-fam proteins,
known to be involved in virulence/antigenicity of P. vivax.
Drug targets and vaccine candidates in P. vivax
Several proteins that are well known drug targets and vaccine
candidates in P. falciparum are also expressed in P. vivax (Table 2).
Plasmepsin IV, m1-family aminopeptidaese, spermidine synthase,
fructose 1, 6- bisphosphate aldolase, pyridoxal kinase, triosepho-
sphate isomerase, L-lactate dehydrogenase, Hsp90 and Hsp70 are
all well known drug targets in P. falciparum against which inhibitors
are known [14–28]. Some vaccine candidates such as the duffy
receptor precursor, which is unique to P. vivax, were also detected
[3,29,30]. Earlier, sequencing of P. vivax revealed several novel gene
families which are located in the subtelomeric regions [3]. Most
notably, we found at least five members of Pv-fam-a (tryptophan
rich antigen) in patients suffering from vivax malaria (Table 2).
There are at least 36 members of pv-fam-a family of proteins, one of
which has previously been reported to elicit humoral immune
response and hence a probable vaccine candidates [31]. Table 2
contains a list of potential drug targets/vaccine candidates in P. vivax
whose efficacy can be revealed only upon further research.
Comparison of P. vivax proteome with transcriptome
All studies on P. vivax till date have been carried out with either
parasites directly isolated from malaria patients or with isolates
adapted to short term culture. The amount of information available
about the gene expression and protein expression profiles of P. vivax
is limited to two transcriptome studies [5,6] and this proteomics
study. Upon closer examination/inspection of proteins reported in
this study with two transcriptome datasets we found no transcript
evidence for three proteins. These are PVX_114832 (Elongation
factor 1 alpha, putative), PVX_250300 (ADP/ATP transporter on
adenylate translocase, putative) and PVX_220290 (putative cyclo-
philin). This observation is intriguing as the previous two studies
have used parasite materials from two different geographically
distinct regions (one from Thailand and the other from Peru) [5,6].
Furthermore, these studies included the stage specific transcriptome
of intraerythrocytic developmental cycle. Individual differences in
gene expression profiles among field isolates have been proposed to
reflect parasites adaptability in response to host environment
[32,33]. Based on proteomic evidence from the field isolates of P.
vivax, we propose that it is possible that these three genes, for which
no transcript data exists, either reflect an altered physiological state
or are expressed specifically in Indian isolates. This interpretation is
based on the assumption that probes for all P. vivax genes have been
included in the transcriptome analysis.
In addition, we found 14 proteins which show differential
expression at transcript levels in different individuals from the two
transcriptome studies mentioned above, which may relate to
different physiological states [5,6]. These are PVX_122850
(Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, putative), PVX_099275
(hypothetical protein), PVX_080555 (hypothetical protein),
PVX_086990 (vacuolar ATP synthase subunit E), PVX_095195
(ATP-dependent RNA helicase, putative), PVX_099095 (elonga-
tion factor 1B, putative), PVX_121930 (hypothetical protein),
PVX_092630 (hypothetical protein), PVX_098620 (hypothetical
protein), PVX_124190 (hypothetical protein), PVX_113635
(hypothetical protein), PVX_101480 (hypothetical protein),
PVX_087690 (hypothetical protein) and PVX_110810 (Duffy
receptor precursor). As is evident, nine of these are annotated as
hypothetical in PlasmoDB database. Domain analysis of these
hypothetical proteins revealed that two of them have DNA repair
(PVX_099275) and chromatin assembly (PVX_092630) as a
putative function. These could be proteins involved in responding
to environmental cues and modulating pathways that may affect
parasite survival.
Figure 2. Functional profiles of protein expressed by asexual stages of P. vivax. A. Proteins identified in asexual stages were plotted as a
function of their broad functional classification as defined in PlasmoDB or GO. Only one class was assigned to one protein to avoid any redundancy.
Major group in the P. vivax is represented by hypothetical proteins followed by metabolic enzymes, chaperones and proteins involved in virulence. B.
Showing functional plot for hypothetical proteins. About 25% of the hypothetical proteins were assigned to different functional classes on domain
architecture.
doi:10.1371/journal.pone.0026623.g002
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The P. vivax interactome
In order to gain further insight into the functions of the P. vivax
proteins detected in our study, we have constructed an
interactome of the P. vivax proteome. For this, we first looked for
P. falciparum homologs for the proteins detected in our study. We
then selected those homologs for which interaction data was
available in literature and found homologs for their interactors in
the P. vivax genome [34,35]. We then constructed an interactome
consisting of P. vivax proteins detected in our study with other P.
vivax proteins (Figure 3). Of the 153 proteins detected in our study,
we found P. falciparum homologs for 137, 16 proteins were specific
for P. vivax. Interactors for only 68 homologs could be found in
Table 1. List of uniquely expressed proteins in P. vivax isolated from patients.
Serial No. Accession No. Protein Mw/pI Probable function
1 PVX_074690* Variable surface protein Vir4-related 48.4/9.29 Virulence/Antigenicity
2 PVX_096985* Variable surface protein Vir, putative 44.6/5.88 Virulence/Antigenicity
3 PVX_101520* Pv-fam-d protein 49.5/9.7 Virulence/Antigenicity
4 PVX_003525* Hypothetical protein 211.6/4.49 Not Known
5 PVX_089835* RAD protein 398.77/10.01 Virulence/Antigenicity
6 PVX_092995* Tryptophan-rich antigen (Pv-fam-a) 429.99./10.1 Virulence/Antigenicity
7 PVX_118695* Pv-fam-d protein 103.2/9.85 Not Known
8 PVX_003545 Hypothetical protein, conserved 34.4/6.31 Not Known
9 PVX_003555 Hypothetical protein, conserved 119.2/3.82 Not Known
10 PVX_083555 Hypothetical protein 16.5/4 Not Known
11 PVX_090265 Tryptophan-rich antigen (Pv-fam-a) 40.1/6.57 Virulence/Antigenicity
12 PVX_096950 Tryptophan-rich antigen (Pv-fam-a) 39.8/9.92 Virulence/Antigenicity
13 PVX_092990 Tryptophan-rich antigen (Pv-fam-a) 157.5/3.36 Virulence/Antigenicity
14 PVX_112670 Tryptophan-rich antigen (Pv-fam-a) 38.5/6.11 Virulence/Antigenicity
15 PVX_090230 Early transcribed membrane protein (ETRAMP) 15.8/10.78 Virulence/Antigenicity
16 PVX_097880 Hypothetical protein 145/10.33 Not Known
‘*’Refers to proteins only present in P. vivax. Remaining proteins are present in any one species of Plasmodium except P. falciparum.
doi:10.1371/journal.pone.0026623.t001
Table 2. Putative vaccine candidates and drug targets identified in P. vivax isolated from patients.
Potential Drug/Vaccine Targets Putative Function Drug Inhibitors (If known) Ref.
Protein ID Description
PVX_092990 PVX_092995 PVX_112670
PVX_096950 PVX_090265
tryptophan-rich antigen
(Pv-fam-a)
Immune evasion - [3,30]
PVX_093680 Phist protein (Pf-fam-b) Immune evasion [3]
PVX_118695 PVX_101520 Pv-fam-d protein Immune evasion - [3]
PVX_089835 RAD protein (Pv-fam-e) Immune evasion - [3]
PVX_110810 Duffy receptor precursor Invasion - [28]
PVX_086040 Aspartic Protease Plasmepsin
IV
Hemoglobin degradation C2-symmetric compounds encompassing the
1,2-dihydroxyethylene scaffold and a variety of
elongated P1/P19 side chains
[13]
PVX_122425 M1-family aminopeptidase,
putative
hemoglobin digestion hPheP[CH2]Phe, Co4, and Bestatin [14,15]
PVX_092065 Spermidine synthase, putative Spermine synthesis cyclohexylamine, dicyclohexylamine [16]
PVX_118255 Fructose 1,6-bisphosphate
aldolase, putative
Glycolysis and Invasion - [17–19]
PVX_113935 Pyridoxal kinase Biotin Synthesis 6-diazo-5-oxo-L-norleucine [20]
PVX_118495 Triosephosphate isomerase,
putative
Glycolysis Synthetic interface peptides [21,22]
PVX_116630 Lactate dehydrogenase Glycolysis Gossypol derivatives, oxamate derivatives [23]
PVX_087950 Hsp90 Signal transduction, Cell
proliferation
Geldanamycin, 17AAG [24,25]
PVX_089425 Hsp70 Chaperone activity pyrimidinone-amides [26,27]
doi:10.1371/journal.pone.0026623.t002
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literature and these were extrapolated to form the P. vivax
interactome. In total, 309 interactions were included. Interestingly,
many of the proteins found in our study form highly intercon-
nected and busy networks in the parasite with unannotated
hypothetical proteins indicating that these could be Plasmodium-
specific pathways. For instance, MCM3, involved in chromosome
maintenance, interacts directly with PVX_098620 and forms a
network indirectly with SET domain containing protein and
PVX_113635. Another highly interconnected hub is formed by
Hsp86, nucleosome assembly protein 1 and Cg4, all of which have
been detected in our study. Interestingly, Hsp86 is indirectly
associated with Duffy receptor protein through Cg4 (member of
Hsp70 family) indicating its involvement in virulence of the
parasite. The P. vivax interactome for the proteins detected in our
study indicate that highly interconnected and possibly active
regulatory networks exist in the parasite, and several vivax-specific
networks are awaiting discovery.
Discussion
Research on human malaria caused by P. vivax has not received
the attention that it deserves due to several factors. Firstly, unlike
P. falciparum, P. vivax is not amenable to laboratory culture.
Secondly (and more importantly), P. vivax, untill recently, was
considered to be a parasite that causes mild and non-fatal disease.
However, recent studies have shown that, in malaria endemic
countries, like India, Indonesia, Papuea New Guinea, approxi-
mately 27% of the patients with severe malaria symptoms are due
to P. vivax infection [36]. As with P. falciparum, drug resistance
poses a severe problem in the treatment of vivax-malaria. Drug
resistant strains of P. vivax have evolved against commonly used
anti-malarials such as chloroquine, primaquine and sulphadoxine-
pyrimethamine [37–39]. Notwithstanding the recent advances in
global studies of P. vivax by transcriptomics and next generation
sequencing [5,6,40], the amount of knowledge that exists about P.
Figure 3. Interaction network of the proteins identified in P. vivax from patient. Interaction network of P. vivax proteins detected in our
study has been constructed based on the presence of interactions of their P. falciparum homologs. The P. vivax proteins which have been detected in
our study have been colored as red nodes. Many proteins detected in P. vivax from malaria patients form highly interconnected hubs showing the
regulatory role of these proteins in several processes in vivax malaria. The major nodes have been indicated with an enlarged font and are
hyperlinked to PlasmoDB.
doi:10.1371/journal.pone.0026623.g003
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vivax is insufficient to understand its biology that will enable
discovery of newer drug targets against the parasite.
Although transcriptome analysis documents a complete picture
of the mRNA complement of a cell, they provide an inadequate
view of the operational cellular protein networks. The absence of
long term cultures of P. vivax both necessitates and provides us with
an opportunity to study this parasite in the wild, i.e. directly from
malaria-infected patients. In this context, it is essential to study the
proteome of P. vivax in order to identify the molecular factors
involved in P. vivax patho-biology. Proteomic analysis of the
clinical isolates of Plasmodium is a difficult task owing to the low
parasitemia and masking of parasite proteins by abundant host
proteins.
Despite these technical shortcomings, we were able to isolate P.
vivax parasites from patient’s samples to enable a proteomic
analysis. Although we could not completely eliminate host protein
contamination, we were able to detect 153 P. vivax proteins in our
study. Besides parasite proteins, we detected about 315 proteins of
host-origin (Table S3). Of these, about 212 (Table S5) have been
detected at transcript levels in the human reticulocyte transcrip-
tome [41]. The other proteins may be from reticulocytes or
remnants of other contaminating human blood cells such as
leukocytes that have not been successfully removed from the
sample.
Additionally, 29 P. vivax proteins were detected for which no MS
based evidence is available in any other Plasmodium species (Table
S3). Majority (about 36%) of the detected P. vivax proteins
consisted of hypothetical proteins. Further domain analysis by
Pfam and SMART databases revealed putative function for 16 out
of 55 hypothetical proteins detected in this study (Table S2).
Amongst the 99 proteins with known function, enzymes involved
in general metabolic functions were heavily represented (22
proteins), followed by proteins involved in chaperoning function
(14) and translation (13) (Figure 2A). Several of these proteins are
targets for chemotherapeutic interventions (Table 2). Notably,
some of these proteins like PfA-M1, Spermidine synthase, Lactate
dehydrogenase and hsp90 have been validated as drug targets.
Besides some of the known drug targets, several proteins with
immunogenic properties were detected which can be further
exploited for designing vaccines. Most importantly, we found that
the members of Pv-fam-a family (Tryptophan rich antigens) of
proteins were abundantly expressed in the field isolates of P.vivax
which warrants further evaluation of their candidature as vaccines.
Figure 4 schematically describes the localization of the identified
Figure 4. Schematic representations of pathways operational in the P. vivax from patient. The figure depicts the cellular localization of the
identified proteins. Proteins indicated in blue represent the ones detected in the clinical isolate of P. vivax and black shows the pathways they are
involved in. ‘2l ’ indicates potential targets for anti-malarials.
doi:10.1371/journal.pone.0026623.g004
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proteins in P. vivax and also gives a snap-shot of the biochemical
pathways that would be operational in the clinical state of P. vivax.
We provide evidence for expression of four proteins which were
hitherto not detected at the transcript level in earlier genome-wide
analysis. This discrepancy can be explained in part due to an
altered physiological state of the parasite in response to the host
environment, though differential expression of genes by parasites
from geographically distinct regions cannot be ruled out. The chief
difference between the previous transcriptome analysis and this
proteomics study lies in the regions of the world from where P.
vivax samples have been collected. The two transcriptome analyses
have collected samples from Thailand and Peru whereas our
samples are from Mangalore, India. It is possible that dif-
ferent strains of P. vivax express marginally different protein
complements.
An important finding of our study was the presence of 16
proteins that are entirely unshared by P. falciparum indicating that
these proteins are likely involved in P. vivax specific infection. This
is interesting considering the significant differences between P.
falciparum and P. vivax infection such as preference for different host
cells and extent of sequestration within host capillaries. It is
possible that the unique proteins detected in our study are involved
in important vivax-specific pathways.
This is the first proteomics analysis of P. vivax-an important first
step towards understanding of P. vivax cell biology. Through this
study, we have identified the most abundant proteins expressed in
clinical P. vivax during its infection of the host such as possible
regulatory proteins and strain specific proteins (Figure 4). These
proteins provide a glimpse of the cellular pathways operational in
the parasite. One limitation of this study is that, it was carried out
with P. vivax samples pooled from different donors and hence we
could not associate in-vivo parasite biological states with host
environment, such as immune status of the patient. To better
appreciate the host-parasite dynamics, additional cohort studies
involving patients with asymptomatic parasitemia, mild and severe
disease are required. This will not only facilitate identification of
molecular factors important for clinical manifestation of malaria
but will also lead to designing of better chemotherapeutic or
vaccine intervention strategies.
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